Here are the 10-Q quarterly reports from Mural Oncology plc (MURA) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MURA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MURA filings page.
Mural Oncology plc (MURA) filed its Q3 2025 10‑Q, reporting a pending all‑cash acquisition by XOMA Royalty Corporation. Shareholders approved the deal, which provides a base cash price of $2.035 per share and up to an additional $0.205 per share, subject to closing conditions.
The company ended the quarter with cash and cash equivalents of $58.9 million and reported a Q3 net loss of $3.7 million. Year‑to‑date, net loss was $84.8 million, with cash used in operations of $86.6 million. A change in estimate after closing out ARTISTRY‑6 reduced R&D expense by about $4.8 million in Q3.
Mural previously discontinued all clinical development of nemvaleukin following unfavorable trial results, ceased preclinical programs, and completed a ~90% workforce reduction, incurring $17.5 million in restructuring and impairment during the nine‑month period. The company disclosed substantial doubt about its ability to continue as a going concern pending completion of the XOMA transaction. As of November 3, 2025, 17,344,486 ordinary shares were outstanding.